13F Filings History of Eversept Partners, LP
- Latest 13F filing
- Q2 2026 - 14 Aug 2026
- Latest reported 13F value
- $1,834,367,679
- Largest 13F holdings
-
UTHR ABVX EHC ENSG VERA CLDX SNDX BKD IONS NTRA TVTX CTRE
+8 more
HCA PCVX LQDA CYH GSK CHE LLY GERN - Form 13F summary
-
- Eversept Partners, LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- Eversept Partners, LP reported 115 equity holdings with a total reported market value of $1,834,367,679 for Q2 2026. Top reported holdings included UTHR, ABVX, EHC, ENSG, and VERA.
- Manager signature
- Ron Rosenstraus - Chief Financial Officer
- Manager location
- New York, NY
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Eversept Partners, LP with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q2 2026
Latest value
$1,834,367,679
Quarter delta
+$316,918,523
Accepted
14 Aug 2026, 11:54
Rows shown
1-25 of 43
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 115 | $1,834,367,679 | +$564,799,617 | -$412,569,238 | +$152,230,379 | UTHR, ABVX, EHC, ENSG, VERA | 13F-HR | 14 Aug 2026, 11:54 |
| Q1 2026 | 104 | $1,517,449,156 | +$404,794,738 | -$601,339,748 | -$196,545,010 | UTHR, ABVX, GSK, VERA, NTRA | 13F-HR | 15 May 2026, 10:51 |
| Q4 2025 | 103 | $1,783,428,441 | +$501,389,551 | -$311,136,457 | +$190,253,094 | VERA, GSK, UTHR, ABVX, NTRA | 13F-HR | 17 Feb 2026, 10:50 |
| Q3 2025 | 83 | $1,305,646,781 | +$405,231,058 | -$233,835,476 | +$171,395,582 | UTHR, GSK, NTRA, VERA, SNDX | 13F-HR | 14 Nov 2025, 11:34 |
| Q2 2025 | 67 | $992,228,456 | +$276,192,868 | -$185,904,332 | +$90,288,536 | NTRA, GSK, VERA, RVTY, PCVX | 13F-HR | 14 Aug 2025, 11:41 |
| Q1 2025 | 55 | $883,687,039 | +$228,856,792 | -$231,300,407 | -$2,443,615 | NTRA, GSK, HCA, SNDX, VERA | 13F-HR | 15 May 2025, 10:41 |
| Q4 2024 | 62 | $969,066,469 | +$168,745,437 | -$400,593,410 | -$231,847,973 | NTRA, GSK, VERA, INSP, HCA | 13F-HR | 14 Feb 2025, 10:13 |
| Q3 2024 | 65 | $1,303,596,522 | +$145,188,874 | -$326,148,343 | -$180,959,469 | GSK, NTRA, VERA, INSM, SNDX | 13F-HR | 14 Nov 2024, 09:08 |
| Q2 2024 | 72 | $1,306,688,227 | +$256,257,689 | -$270,238,491 | -$13,980,802 | GSK, NTRA, INSM, TEVA, UTHR | 13F-HR | 14 Aug 2024, 09:03 |
| Q1 2024 | 68 | $1,338,095,549 | +$248,505,649 | -$158,505,705 | +$89,999,944 | NTRA, GSK, INSP, TEVA, VERA | 13F-HR | 15 May 2024, 08:40 |
| Q4 2023 | 55 | $1,019,780,533 | +$200,202,063 | -$184,000,271 | +$16,201,792 | NTRA, GSK, SNDX, INSP, TEVA | 13F-HR | 14 Feb 2024, 08:50 |
| Q3 2023 | 61 | $900,715,192 | +$165,102,013 | -$149,989,603 | +$15,112,410 | GSK, NTRA, TEVA, UTHR, INSP | 13F-HR | 14 Nov 2023, 14:07 |
| Q2 2023 | 66 | $946,893,078 | +$185,367,863 | -$324,331,202 | -$138,963,339 | NTRA, GSK, TEVA, UTHR, HZNP | Restatement | 08 Nov 2023, 14:50 |
| Q1 2023 | 58 | $1,112,501,187 | +$278,423,548 | -$230,984,486 | +$47,439,062 | NTRA, GSK, HZNP, TEVA, UTHR | Restatement | 08 Nov 2023, 14:48 |
| Q4 2022 | 3 | $342,366 | $0 | $0 | $0 | ELDN, SNDA, BOLT | New Holdings | 08 Nov 2023, 14:46 |
| Q4 2022 | 62 | $1,051,612,933 | +$334,553,429 | -$264,947,922 | +$69,605,507 | GSK, HZNP, NTRA, SNY, UTHR | Restatement | 08 Nov 2023, 14:44 |
| Q3 2022 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:42 | |
| Q3 2022 | 60 | $843,153,820 | +$230,222,677 | -$364,330,367 | -$134,107,690 | BHVN, GSK, HZNP, NTRA, UTHR | Restatement | 08 Nov 2023, 14:40 |
| Q2 2022 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:38 | |
| Q2 2022 | 65 | $1,023,939,921 | +$344,482,609 | -$265,574,004 | +$78,908,605 | BHVN, UTHR, HZNP, GSK, AZN | Restatement | 08 Nov 2023, 14:37 |
| Q1 2022 | 76 | $1,084,513,902 | +$253,982,943 | -$304,515,350 | -$50,532,407 | CYH, BHVN, HZNP, GSK, UTHR | Restatement | 08 Nov 2023, 14:35 |
| Q4 2021 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:33 | |
| Q4 2021 | 90 | $1,201,454,859 | +$239,172,339 | -$280,766,349 | -$41,594,010 | HZNP, CYH, UTHR, DHR, AZN | Restatement | 08 Nov 2023, 14:31 |
| Q3 2021 | 0 | $0 | $0 | $0 | $0 | New Holdings | 08 Nov 2023, 14:29 | |
| Q3 2021 | 88 | $1,245,968,450 | +$384,301,715 | -$228,274,696 | +$156,027,019 | UTHR, ASND, CYH, HZNP, XLRN | Restatement | 08 Nov 2023, 14:28 |